Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)
Rhea-AI Summary
Aligos Therapeutics (Nasdaq: ALGS) reported positive clinical data presented at CROI (Feb 22–25, 2026) from two posters: a Phase 1 monotherapy study of pevifoscorvir sodium showing high viral suppression in chronic HBV, and pharmacokinetics data for ALG-097558 in hepatic and renal impairment.
The ALG-097558 work acknowledges partial federal funding under Contract No. 75N93023C00052 and presentations were scheduled Feb 23 and Feb 25, 2026 in Denver.
Positive
- None.
Negative
- None.
News Market Reaction – ALGS
On the day this news was published, ALGS gained 2.06%, reflecting a moderate positive market reaction. This price movement added approximately $893K to the company's valuation, bringing the market cap to $44.24M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ALGS was down 4.49% while key biotech peers showed mixed moves: IGMS -2.31%, ACET -2.06%, CVM -3.03%, and ENTX +6.52%. Only one separate peer (PRLD, +1.08%) appeared on the momentum scanner, indicating today’s move looked more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 30 | Inducement equity grants | Neutral | -0.6% | Inducement stock options for 81,100 shares granted to new employees. |
| Jan 21 | Phase 2 study update | Neutral | -0.1% | B-SUPREME Phase 2 pevifoscorvir update with interim analyses timing and CMO change. |
| Jan 13 | CCO appointment | Positive | +6.1% | Appointment of Chief Commercial Officer to build global commercial capabilities. |
| Dec 12 | Inducement equity grants | Neutral | +15.5% | Non-qualified options for 14,100 shares granted under 2024 Inducement Plan. |
| Dec 11 | Positive trial data | Positive | +1.6% | Positive HEP-DART 2025 data for pevifoscorvir and obesity combo candidate ALG-055009. |
Across the last five news events, all observed price reactions aligned with the apparent news tone, with modest moves around clinical and leadership updates and occasionally larger reactions to corporate or equity-related announcements.
Recent news for Aligos has focused on clinical progress and corporate housekeeping. A Jan 21, 2026 update confirmed Phase 2 B‑SUPREME enrollment tracking to plan, while a Jan 13, 2026 appointment of a Chief Commercial Officer aligned with preparations for later‑stage development of pevifoscorvir sodium. Inducement grant announcements in Dec 2025 and Jan 2026 prompted mixed but generally aligned price reactions. Today’s CROI data presentation continues the pattern of emphasizing HBV and coronavirus programs.
Market Pulse Summary
This announcement highlights positive CROI data for pevifoscorvir sodium in chronic HBV and ALG-097558 in hepatic and renal impairment, reinforcing Aligos’ focus on liver and viral diseases. Earlier updates in 1H 2026 and late 2025 also centered on advancing pevifoscorvir and related programs. Investors may track forthcoming Phase 2 B‑SUPREME milestones, additional coronavirus data, and any new regulatory or financing disclosures to gauge how these assets progress toward later-stage development.
Key Terms
monotherapy medical
chronic hepatitis B virus medical
hepatic impairment medical
renal impairment medical
protease inhibitor medical
pharmacokinetics medical
AI-generated analysis. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from two presentations at the Conference on Retroviruses and Opportunistic Infections (CROI), being held February 22 – 25, 2026 in Denver, Colorado.
The pevifoscorvir sodium presentation highlights the Phase 1 monotherapy study of pevifoscorvir sodium, a potent CAM-E under development for the treatment of chronic hepatitis B virus (HBV) infection. Additionally, the ALG-097558 presentation showcases data from participants with hepatic and renal impairment. The ALG-097558 project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (HHS), under Contract No. 75N93023C00052.
“We are pleased to continue showcasing the best/first-in-class pevifoscorvir sodium data from the Phase 1 study in participants with chronic HBV infection,” said Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and CEO of Aligos Therapeutics. “Additionally, we continue to move our COVID program forward with grants from government agencies and are pleased to show some of this important clinical work at CROI this year.”
Details of the presentations are as follows:
Pevifoscorvir sodium: Potential first-/best-in-class small molecule CAM-E under investigation for chronic hepatitis B virus (HBV) infection
Poster #: 588
Title: High Viral Suppression in Chronic HBV Infection Subjects with Pevifoscorvir Sodium Monotherapy
Presenter: Stanley Wang, MD
Date/Time: February 23, 2026, 2:30pm – 4:00pm MST
Session: Beyond the C: Hepatitis D, B, and E
ALG-097558: Potential best-in-class ritonavir-free small molecule pan-coronavirus protease inhibitor
Poster #: 737
Title: Pharmacokinetics of ALG-097558, a Pan-Coronavirus 3CL-Pro Inhibitor, in Renal and Hepatic Impairment
Presenter: Megan Fitzgerald, PhD
Date/Time: February 25, 2026, 2:30pm – 4:00pm MST
Session: SARS-CoV-2 Therapy, Consequences, and Outcomes
The presentations can be found on the Posters & Presentations section of the Aligos website (www.aligos.com) after the live event.
About Aligos
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus (HBV) infection, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.
For more information, please visit www.aligos.com or follow us on LinkedIn or X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Investor Contact
Aligos Therapeutics, Inc.
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com
Media Contact
Inizio Evoke
Jake Robison
Vice President
Jake.Robison@inizioevoke.com
